Journal of Antimicrobial Chemotherapy (2002) 49, 239-241
© 2002 The British Society for Antimicrobial Chemotherapy
Leading articles |
New antifungal agents—treatment standards are beginning to grow old
Charité University Hospital, Campus Virchow-Klinikum, Department of Haematology and Oncology, Augustenburger Platz 1, D-13353 Berlin, Germany
During the past two decades, significant progress has been made in the management of infectious complications in patients with malignancies. The intensification of antineoplastic therapy and transplant procedures was enabled by stringent guidelines for the early diagnosis of infections and systematically escalated antimicrobial treatment, both based upon large prospective clinical studies. A broad spectrum of highly efficacious antibiotic and antiviral agents have helped to reduce the mortality from invasive bacterial or viral infections to <5–10% in these patients. At the same time, systemic and deep organ fungal infections have become the leading causes of death among patients with aggressive haematological malignancies and among transplant recipients.1 Sophisticated guidelines for the classification2 and treatment3,4 of Candida and Aspergillus infections published by expert committees are helping clinicians to use their limited armamentarium of
Voriconazole
Intravenous itraconazole
Caspofungin
Open questions
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Lincopan, E. M. Mamizuka, and A. M. Carmona-Ribeiro Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments J. Antimicrob. Chemother., May 1, 2005; 55(5): 727 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lincopan, E. M. Mamizuka, and A. M. Carmona-Ribeiro In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments J. Antimicrob. Chemother., September 1, 2003; 52(3): 412 - 418. [Abstract] [Full Text] [PDF]
|
|